Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

The addition of Gemtuzumab Ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial

Burnett, Alan Kenneth, Hills, Robert Kerrin, Hunter, Ann E., Milligan, Donald, Kell, William J., Wheatley, Keith, Yin, John L., Ali, Sahra, Kjeldsen, Lars, Bowen, David and Russell, Nigel H. 2011. The addition of Gemtuzumab Ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial. Blood -New York- 118 (21) , p. 268.

Full text not available from this repository.
Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
R Medicine > RC Internal medicine
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
Additional Information: Conference: 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis Location: San Diego, CA Date: DEC 10-13, 2011
Publisher: American Society of Hematology
ISSN: 0006-4971
Last Modified: 19 Oct 2019 02:56
URI: http://orca-mwe.cf.ac.uk/id/eprint/49786

Citation Data

Cited 32 times in Google Scholar. View in Google Scholar

Actions (repository staff only)

Edit Item Edit Item